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MicroarrayInsulin resistance (IR) is a physiological condition in which cells fail to respond to the insulin hormone. Despite
advances in the diagnosis and treatment of IR, novelmolecular targets are still needed to improve the accuracy of
diagnosis and the outcomes of therapy.Here,we present a systems approach to identifymolecular biomarkers for
IR.We downloaded the gene expression proﬁle of IR from the Gene Expression Omnibus (GEO), generated a reg-
ulatory network by mapping co-expressed genes to transcription factors (TFs) and calculated the regulatory
impact factor of each transcription factor. Finally, we selected a list of potential molecular targets that could be
used as therapeutic targets or diagnostic biomarkers, including ETS1, AR, ESR1 and Myc. Our studies identiﬁed
multiple TFs that could play an important role in the pathogenesis of IR and provided a systems understanding
of the potential relationships among these genes. Our study has the potential to aid in the understanding of IR
and provides a basis for IR biomarker discovery.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Insulin regulates glucose uptake and circulating free fatty acid (FFA)
concentrations. Insulin resistance (IR) is deﬁned as an impaired sensi-
tivity to insulin in its main target organs: adipose tissue, the liver and
muscle. IR is primarily manifested in the skeletal muscle and adipose
tissue, which fail to take up adequate glucose. Elevated glucose produc-
tion in the liver also occurs, and IR increases circulating FFA concentra-
tions and causes ectopic fat accumulation. In recent years, increasing
evidence has emerged that obesity is associated with inﬂammation
that is causally involved in the development of IR. Most importantly,
IR has been established as a precursor of type 2 diabetes (T2D)
(Harris, 1995; Lyssenko et al., 2008) and cardiovascular diseaseExpression Omnibus; FFA, free
ycemia; IGT, impaired glucose
insulinemic euglycemic clamp;
rance test; FSIVGTT, frequently
roxybutyrate; GDF-15, growth
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ogy Information; DAVID, The
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n receptor 1; MYC, v-myc
nalcoholic fatty liver disease;
V. Open access under CC BY-NC-ND lic(Ferrannini et al., 2007; Lima et al., 2009; Reaven, 2008). Along with
hyperinsulinemia and β-cell dysfunction, IR is a major pathophysiolog-
ical determinant of dysglycemia (impaired fasting glycemia (IFG) and
impaired glucose tolerance (IGT)) and T2D (Abdul-Ghani and
DeFronzo, 2009;Defronzo, 2009). Conditions of high cardiovascular dis-
ease (CVD) risk, such as hypertension, dyslipidemia and atherosclerosis,
have also been associatedwith IR (Biddinger et al., 2008;Mulvihill et al.,
2011).
Although a variety of methods for measuring IR have been devel-
oped, there is a need for new biological markers that can be used to de-
tect IR. Current methods include the gold-standard hyperinsulinemic
euglycemic clamp (HI clamp), the insulin tolerance test, steady state
plasma glucose (SSPG) following ﬁxed somatostatin/glucose/insulin in-
fusions andmodeling based on the oral glucose tolerance test (OGTT) or
the frequently sampled intravenous glucose tolerance test (FSIVGTT)
(Bergman, 2007). However, these procedures are mostly conﬁned to
clinical research settings due to cost and time constraints. Fasting insu-
lin and derived indices (HOMA, QUICKI) have been widely used
(Muniyappa et al., 2008), but a lack of insulin measurement standardi-
zation strongly limits their accuracy and has prevented their adoption
in routine clinical practice. In fact, in recent years, many insulin
resistance-related biomarkers have been conﬁrmed, such as a-
hydroxybutyrate (a-HB) (Gall et al., 2010), growth and differentiation
factor-15 (GDF-15) (Vila et al., 2011), soluble CD163 (Parkner et al.,
2012), adiponectin (Lu et al., 2008), circulating fatty acid synthase
(FASN) (Fernandez-Real et al., 2010) and YKL-40 (Rathcke et al.,ense.
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mechanism of insulin resistance but also serve as signs for identifying
individuals at risk of progression to insulin resistance. These biomarkers
have the potential to provide simple and effective strategies for disease
prevention and patient monitoring.
In this paper, we introduce a systems approach that can be used for
the discovery of new molecular biomarkers for IR. Based on gene
expression data, we reconstructed a regulatory network and selected
a list of potential molecular targets that could be used for the discovery
of therapeutic targets and diagnostic biomarkers. These targets may
also provide novel insights into IR pathogenesis.2. Methods
2.1. Affymetrix microarray analysis
We obtained gene expression datasets (Table 1) from the NCBI
(National Center for Biotechnology Information) GEO (Gene Expression
Omnibus) (http://www.ncbi.nlm.nih.gov/geo/) database. By using
“insulin resistance” as a search term, we found 57 human expression
datasets in the database through 2013. We chose three datasets for
our analysis based on three criteria. First, these datasets contain both
insulin-resistant and insulin-sensitive samples. Second, the three
datasets examine different tissues. Finally, each of the three datasets
has a sufﬁcient number of insulin-resistant samples. In these datasets,
we considered only the samples that are insulin sensitive (IS) or insulin
resistant (IR) and come from different human organs. The original
expression datasets fromall of the chipswere processed into expression
estimates using the RMAmethod (robustmulti-array average) with the
default settings as implemented in Bioconductor. Next, a linear model
was constructed. The differentially expressed genes (DEG) were
extracted by using a t-test with a p-value cutoff of 0.05.2.2. Differential co-expression analysis
To determine the correlations of gene pairs in the datasets, we used
the CoExpress tool (http://www.bioinformatics.lu/CoExpress/), which
is a user-friendly software tool for the interactive comparison of
expression proﬁles. CoExpress can be used to build pairwise gene co-
expression matrices.
For each co-expression gene pair, we also used the DiffCorr package
in R (Fukushima, 2012) to export a list of signiﬁcantly differential
correlations as a text ﬁle. This package can calculate the differences in
the correlations, the corresponding p-values and the results of Fisher's
z-test while controlling false discovery rates (FDR).2.3. Construction of the IR regulatory network
To reconstruct an IR regulatory network from the co-expressed gene
pairs, we ﬁrst downloaded the set of human transcriptional regulation
interactions from HTRIdb (Bovolenta et al., 2012). HTRIdb is a reposito-
ry of experimentally veriﬁed interactions between human TFs and their
respective target genes. We constructed an IR regulatory network
model based on the regulatory interactions between the co-expressed
gene pairs.Table 1
Gene expression datasets used in this study.
Sample origin Sample type
and numbers
Raw data
source ID
Reference
Skeletal muscle 20 IS, 20 IR GSE22309 Wu et al. (2007)
Adipose tissue 20 IS, 19 IR GSE20950 Hardy et al. (2011)
Hepatokines 7 IS, 10 IR GSE23343 Misu et al. (2010)2.4. Computation of the regulatory impact factor
The regulatory impact factor (RIF) appears to be a robust and valu-
able methodology for identifying the regulators that show the highest
evidence of contributing to differential expression under two different
biological conditions. The RIF is a metric assigned to each TF that com-
bines the change in co-expression of the TF and its potential targets.
The RIF is computed as described by Reverter et al. (2010).2.5. Pathway enrichment analysis
To facilitate the functional annotation and analysis of large lists of
genes, we used DAVID (The Database for Annotation, Visualization
and Integrated Discovery) for KEGG (Kyoto Encyclopedia of Genes and
Genomes) term enrichment analysis. DAVID identiﬁes the canonical
pathways that are associated with a given list of genes by calculating
the hypergeometric test p-value for the probability of an association
between this set of genes and a canonical pathway (Huang da et al.,
2009). A p-value of less than 0.05 and a count greater than 2 were cho-
sen as the cut-off criteria. We calculated the p-values and adjusted the
raw p-values to obtain FDR by using the Benjamini–Hochberg method
for multiple-testing correction.3. Results
3.1. Identiﬁcation of differentially expressed genes in IR
To identify co-expressed gene pairs involved in IR in different tis-
sues, we downloaded the publicly available microarray datasets
GSE22309, GSE20950 and GSE23343 from the GEO database and used
the CoExpress tool to identify co-expressed gene pairs between IR and
normal samples. We found 1775 genes with 173,206 co-expressed
gene pairs in skeletal muscle, 3774 genes with 596,396 co-expressed
gene pairs in adipose tissue and 10,089 genes with 411,194 co-
expressed gene pairs in hepatokines. A total of 355 genes were identi-
ﬁed in all three tissues (Fig. 1).We calculated the statistical signiﬁcance
of gene overlap between each pair of groups using the hypergeometric
distribution. The p-values were far less than 0.05, indicating that the
overlap between these sets does not occur by chance.Fig. 1. Venn diagram that shows the co-expression genes in the three datasets.
Fig. 2.A. Regulatory network among TFs and their target genes for IR in the skeletalmuscle. The red nodes represent TFs, and the green nodes represent their target genes. The large nodes
are differentially expressed genes, and the small nodes are non-DEGs. B. Regulatory network among TFs and their target genes for IR in adipose tissue. The red nodes represent TFs, and the
green nodes represent their target genes. The large nodes are differentially expressed genes, and the small nodes are non-DEGs. C. Regulatory network among TFs and their target genes
for IR in hepatokines. The red nodes represent TFs, and the green nodes represent their target genes. The large nodes are differentially expressed genes, and the small nodes are non-DEGs.
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To construct the regulatory network, we matched all of the genes
and co-expressed gene pairs to the known regulatory data fromHTRIdb
for transcription factors and their target genes. We obtained three reg-
ulatory networks for the three tissues with IR. To clearly show the reg-
ulatory relationships, we analyzed the three regulatory networks using
Cytoscape. We found 308 pairwise relationships between 14 TFs and
266 target genes in skeletal muscle (Fig. 2), 364 pairwise relationships
between 14 TFs and 345 target genes in adipose tissue (Fig. 2B) and
331 pairwise relationships between 26 TFs and 305 target genes in
hepatokines (Fig. 2C).3.3. Enrichment of IR-associated pathways
To gain further insight into the functions of genes in our regulatory
network, we used the online biological classiﬁcation tool DAVID and
observed a signiﬁcant enrichment of speciﬁc genes in multiple KEGG
categories (Table 2). The pathway analysis revealed that the genes in
skeletal muscle were strongly associated with the ribosome and the
genes in adipose were related to cancer. In hepatokines, the genes
were strongly associated with long-term depression and a few of the
genes were related to the insulin signaling pathway.3.4. Impact analysis of transcription factors
The three regulatory networks generate vast amounts of data. To
focus on the most meaningful information, we calculated the RIF of
each TF. The top ﬁve TFs in the three tissues are shown in Table 3.
ETS1 (v-ets erythroblastosis virus E26 oncogene homolog 1) is an
important gene for IR in all of the tissues. AR (androgen receptor) was
found in both adipose tissue and hepatokines with a high rank. ESR1
(estrogen receptor 1) may play an important role in IR in the skeletal
muscle and hepatokines, butMYC (v-mycmyelocytomatosis viral onco-
gene homolog) was found only in the skeletal muscle and adipose
tissue.
4. Discussion
IR is associated with hyperinsulinemia, dyslipoproteinemia, hyper-
tension and abnormalities of several nontraditional risk factors, such
as endothelial dysfunction, abnormal ﬁbrinolysis and inﬂammation
(Hong et al., 2007; Stern and Izkhakov, 2006). This complex metabolic
disorder is a very important risk factor for obesity-associated diseases,
including metabolic syndrome, nonalcoholic fatty liver disease
(NAFLD), type 2 diabetes (T2D) and atherosclerotic heart disease
(Samuel and Shulman, 2012). Although many experiments have illus-
trated the mechanism for the development of insulin resistance, few
Table 2
The top 10 most enriched KEGG pathways in the three tissues.
GeneSet Number of genes in set Genes from network p-Value FDR
Skeletal muscle
Ribosome 91 24 0 2.50e−04
Dopaminergic synapse 130 10 0 8.00e−04
Oxidative phosphorylation 133 10 0 6.67e−04
Alzheimer's disease 168 11 0 5.71e−04
Cholinergic synapse 112 8 0.0002 8.88e−03
Cell cycle 124 8 0.0003 1.76e−02
Long-term depression 70 6 0.0004 1.84e−02
Chagas disease 104 7 0.0006 2.29e−02
Oocyte meiosis 112 7 0.001 2.69e−02
Huntington's disease 184 9 0.0011 2.74e−02
Adipose tissue
Pathways in cancer 325 23 0 3.33e−04
HTLV-I infection 263 17 0 2.00e−04
Osteoclast differentiation 132 11 0 1.00e−04
ECM–receptor interaction 85 8 0 4.00e−04
Prostate cancer 89 8 0 4.71e−04
Chagas disease 104 8 0.0001 1.36e−03
Dorso-ventral axis formation 24 4 0.0003 3.49e−03
Transcriptional misregulation in cancer 179 9 0.0007 5.61e−03
Oocyte meiosis 112 7 0.0008 5.56e−03
TGF-beta signaling pathway 84 6 0.001 6.12e−03
Hepatokines
Long-term depression 70 7 0.0001 2.27e−03
Thyroid cancer 29 5 0.0001 2.28e−03
Renal cell carcinoma 70 7 0.0001 2.28e−03
Non-small cell lung cancer 54 6 0.0001 3.31e−03
Ubiquitin mediated proteolysis 137 9 0.0002 3.47e−03
mRNA surveillance pathway 90 7 0.0003 5.86e−03
Pathways in cancer 325 13 0.0008 8.70e−03
Insulin signaling pathway 138 8 0.0008 9.53e−03
B-cell receptor signaling pathway 77 6 0.0009 8.89e−03
Endometrial cancer 52 5 0.0009 9.26e−03
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molecular biomarkers have substantial potential for use in the screen-
ing, diagnosis, prognosis and monitoring of disease. Microarrays have
been widely used in the discovery of disease biomarkers because they
can interrogate the expression levels of thousands of genes in the
human genome simultaneously (Cooper et al., 2007; Guttula et al.,
2012). In the present study, we analyzed microarray data integrated
with regulatory network data to discover transcription factors that po-
tentially cause the dysregulation observed in insulin resistance.
First, we highlight ETS1, which was ranked highest for both the
skeletal muscle and hepatokines and second for the adipose tissue.Table 3
The top 5 ranked TF in different tissues.
Tissue TF RIF Rank
Skeletal muscle ETS1 322,176.2 1
Skeletal muscle E2F4 261,147.2 2
Skeletal muscle FOXA1 130,995.4 3
Skeletal muscle ESR1 124,479.8 4
Skeletal muscle MYC 116,652.9 5
Adipose tissue AR 293,364.1 1
Adipose tissue ETS1 187,232.4 2
Adipose tissue MYC 150,098.9 3
Adipose tissue JUN 139,987.3 4
Adipose tissue FOS 112,009.8 5
Hepatokine ETS1 268,920.0 1
Hepatokine ESR1 189,007.0 2
Hepatokine AR 144,892.5 3
Hepatokine GATA1 133,077.5 4
Hepatokine YBX1 110,864.4 5ETS transcription factors have been implicated in the regulation of
genes involved in homeostasis, vascular development and angiogenesis
(Dejana et al., 2007).
Evidence indicates that endothelial progenitor cells (EPCs) are
impaired in patients who have coronary artery disease and diabetes; cir-
culating EPCs are reduced in these patients, leading to functional
impairments (Fadini et al., 2006; Gallagher et al., 2007). In fact, Seeger
and his coworkers found that one of the major signals causing EPC dys-
function is the activation of the transcription factor ETS1 (Seeger et al.,
2009). These authors also demonstrated that the downregulation of
ETS1 rescued the diabetes-induced EPC reduction (Seeger et al., 2009).
In terms of IR, very little is known about the mechanisms that might
lead to the inability of EPCs to respond to insulin. Our study reveals a dif-
ferential expression of ETS1 in all three tissues with IR (with or without
hyperglycemia), which suggests that insulin resistance is an independent
risk factor in EPC dysfunction that also acts through the activation of the
ETS1 signaling pathway.
Androgen receptor (AR), a ligand-activated transcription factor, is
activated by androgens and binds as a homodimer to speciﬁc DNA
motifs near its target genes. In males, a substantial amount of evidence
has demonstrated that AR is involved in energy homeostasis. High tes-
tosterone is linked to insulin sensitivity and anti-obesity actions that are
mediated via ARs. Testosterone has been shown to be protective against
the early apoptotic damage that is induced by streptozotocin in the
male rat pancreas, and testosterone acts through an AR-dependent
mechanism (Morimoto et al., 2005; Palomar-Morales et al., 2010).
Total serum testosterone is inversely correlated with the amount of vis-
ceral adipose tissue and with metabolic syndrome (Khaw and Barrett-
Connor, 1992).
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hepatokines in IR samples, which is consistent with results from other
studies. Some scientists found that male mice lacking AR develop late-
onset visceral obesity with increased lipogenesis in thewhite adipose tis-
sue and liver (Fan et al., 2005; Lin et al., 2005). Hung-Yun Lin et al. gener-
ated hepatic AR knockout mice and showed that hepatic AR could play a
vital role in preventing the development of IR and hepatic steatosis (Lin
et al., 2008).
Estrogen receptor 1 (ESR1) is a member of the ESR family of tran-
scription factors. The ESR family is essential for sexual development
and reproductive function, and it is also involved in pathological pro-
cesses, including breast cancer, endometrial cancer and osteoporosis
(Becherini et al., 2000; Fytili et al., 2005; Lamp et al., 2011). Many stud-
ies have shown that ESR1 is involved in age-relatedmetabolic disorders.
ESR1 controls energy intake and expenditure, suppresses lipogenesis in
white adipose and liver tissue, improves insulin sensitivity and
enhances β-cell function and survival (Mauvais-Jarvis, 2011). In addi-
tion, genetic polymorphisms in ESR1 are associatedwith type 2 diabetes
and with fasting plasma glucose levels. The association between T2D
and ESR1 variants may arise because of other unidentiﬁed ESR1 poly-
morphisms that regulate glucose homeostasis (Dahlman et al., 2008).
In a recent study, a genome-wide meta-analysis showed that ESR1
may be the gene with the highest associated T2D genetic risk (Hale
et al., 2012). Other research has also suggested that ESR1 can act as a
predictor of T2D risk (Linner et al., 2013). The differential expression
of ESR1 observed in our study shows once again that ESR1 is associated
with insulin resistance.
Myc is a transcription factor of the basic helix–loop–helix-leucine
zipper (bHLH-LZ) family, which includes factors that promote both pro-
liferation and apoptosis in a variety of cell types (Nasi et al., 2001). The
canonical Myc network controls how the essential nutrients glucose
and glutamine are utilized inside cells. Myc expression is induced in
pancreatic β-cells cultured in the presence of 20–30 mM glucose or
lower glucose concentrations (b5 mM) (Jonas et al., 1999, 2001; Van
de Casteele et al., 2003). The overexpression of Myc in the β-cells of
transgenic mice causes both proliferation and apoptosis (Laybutt et al.,
2002) because of the decreasing insulin expression. In β-cells, Myc
stimulates apoptosis more than proliferation, which leads to a net β-
cell loss and promotes the development of diabetes (Kaneto et al.,
2002; Pelengaris et al., 2002). Cheung et al. also demonstrated that
Myc directly causes impaired insulin secretion and the loss of β-cell
mass in vivo independently of hyperglycemia (Cheung et al., 2010). In
contrast, papers from Bosch's lab show that the transgenic overexpres-
sion of Myc in the liver can counteract obesity and insulin resistance. In
the study, the hepatic overexpression of Myc led to an increase in the
expression of the glucose transporter GLUT2 (Riu et al., 2003). All of
this evidence shows that Myc expression changes are most likely relat-
ed to β-cell function, insulin resistance and diabetes. In our study, we
found that the expression ofMyc in the skeletal muscle and adipose tis-
sue differs in the state of insulin resistance, which also suggests that
Myc is strongly associated with the onset of IR.
As shown in Table 2, someof the signiﬁcantly enriched pathways are
related to cancer, whichmeans that diabetes (especially IR) is related to
cancer. Recent epidemiological and clinical evidence points to a link
between insulin resistance and cancer, but the mechanisms for this
association are still unknown (Arcidiacono et al., 2012). Moreover,
some pathways that are associated with protein synthesis are also
enriched, such as the ribosomal, oxidative phosphorylation and mRNA
surveillance pathways. This pattern suggests that the biological pro-
cesses of protein turnover are impaired in IR.
In conclusion, we have identiﬁed molecular biomarkers for IR by
using a computational bioinformatics analysis of gene expression.
After regulatory network construction and regulatory impact factor
analysis, we found that the transcription factors ESR1, AR, ETS1 and
Myc show altered expression levels and may play important roles in
IR. Previous studies have described the relationships between thesegenes and diabetes/IR, but no systems biology analysis has shown the
important roles of these genes in the regulatory network. We used
regulatory network analysis to show that these genes can serve as bio-
markers for IR.Conﬂict of interest
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